

Transforming Diabetes, Obesity, and Beyond: The GLP-1 Drug Class and its Descendants



Otello Stampacchia
Managing Director
Omega Funds



Marla Jalbut
Associate
Omega Funds

[Watch the Replay](#)

In the Insights Series, the Omega Funds team explores the dynamic landscape of life science investments, offering in-depth discussions on topics vital to the biotech and healthcare sectors. Through this series, Omega aims to foster engagement and knowledge sharing within its network, particularly among Limited Partners and Capital Allocators, by providing valuable insights from experienced investment professionals.

In the latest **Omega Funds Insights Series** webinar, Omega Founder and Managing Director Otello Stampacchia and Investment Associate Marla Jalbut discuss how GLP-1 drugs are reshaping the future of diabetes, obesity and beyond.

Key Highlights:

- ✔ **GLP-1 Revolution:** Discover the groundbreaking role of GLP-1 receptor agonists in transforming the treatment landscape for diabetes and obesity.
- ✔ **Market Impact:** Explore the significant impact of GLP-1 drugs on the pharmaceutical industry, with growing sales projections suggesting the US market could reach over \$150 billion by 2030 in obesity alone. This growth is driving continued interest in innovation and development within the space and will have many indirect consequences throughout the industry.
- ✔ **Navigating the Hype Cycle:** Delve into our application of the Gartner Hype Cycle to GLP-1s, identifying our current stage and forecasting the continued ascent of these drugs, poised for sustained growth amidst a landscape of high expectations and undiscovered potential.
- ✔ **Supply Dynamics:** Explore the challenges and strategic responses in the GLP-1 market, where supply constraints pose hurdles to patient access. We discuss how industry leaders like Novo Nordisk and Eli Lilly are channeling billions into manufacturing expansions to meet the escalating demand.
- ✔ **Beyond Diabetes and Obesity:** Extrapolate the therapeutic impact of GLP-1 receptor agonists in combating other conditions, including heart disease, liver disease, and neurological disorders.
- ✔ **M&A Acceleration:** Observe the intensifying wave of M&A within the cardio-metabolic space, as large pharma companies behind Lilly and Novo try to catch up by seeking novel mechanisms / improved delivery methods to stake a position in this rapidly growing and extremely large market.
- ✔ **Historical Echoes:** Contemplate the potential parallels to historical pharmaceutical innovations leading to very large market impact (i.e. statins for cardiovascular disease, checkpoint inhibitors in cancer).

The GLP-1 drug class represents a significant advancement in the treatment of diabetes, obesity, and potentially many other conditions. As the healthcare industry continues to explore and optimize these drugs, their impact on patient care and global health is expected to be profound.

Interestingly, Dr. Scott Gottlieb, former FDA commissioner, [appeared on CNBC](#) shortly after our webinar and shared insights that mirrored our discussion. He emphasized the significant potential of GLP-1 drugs and the factors that could make them indispensable for insurance coverage. Notably, he drew the same parallel to statins that we highlighted in our discussion, emphasizing the profound medical advance these drugs represent.

Dr. Gottlieb's final comment during the segment, "we're in the early innings of the innovation in this space," resonates with our perspective on the ongoing evolution and impact of these treatments – For investors and stakeholders in the life sciences sector, the GLP-1 drug class represents a dynamic and rapidly evolving field, rich with opportunities for growth and innovation.

The **Omega Funds Insights Series** is dedicated to shedding light on these advancements, informing investment decisions and deepening the collective understanding of the biotech landscape.

[Access the full webinar replay here](#)

We highly value your participation, whether by attending our sessions, asking questions, or sharing perspectives. To stay informed about future Insights Series sessions or to propose topics or speakers, please reach out to us at insights@omegafunds.com.